← Back to Search

Ischemic Conditioning for Peripheral Arterial Disease

N/A
Recruiting
Led By Lindsay Slater, PhD
Research Sponsored by University of Illinois at Chicago
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Be older than 18 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up through study completion, an average of 6 weeks

Summary

This trial will test the effects of ischemic conditioning (IC) on quadriceps strength and walking economy in individuals with lower limb amputation and peripheral artery disease.

Who is the study for?
This trial is for adults over 18 with a history of unilateral lower limb amputation due to peripheral artery disease, who can walk continuously for at least 10 minutes. They must not use walking aids and should have no neurological disorders affecting gait, heart failure, adverse reactions to ultrasound gel, thrombosis, sickle cell trait or hypertension.
What is being tested?
The study tests the effects of ischemic conditioning (IC), which involves repeated cycles of reduced blood flow followed by reperfusion on leg muscles. It aims to see if IC can strengthen quadriceps and improve walking efficiency in people with PAD after an amputation.
What are the potential side effects?
Potential side effects may include discomfort from the compression used during IC treatment and possible muscle fatigue. However, since this is non-invasive there are minimal risks compared to drug treatments.

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~through study completion, an average of 6 weeks
This trial's timeline: 3 weeks for screening, Varies for treatment, and through study completion, an average of 6 weeks for reporting.

Treatment Details

Study Objectives

Study objectives can provide a clearer picture of what you can expect from a treatment.
Primary study objectives
Change in gait kinematics
Change in gait kinetics
Body Weight Changes
+1 more
Secondary study objectives
Six-minute walk test

Trial Design

2Treatment groups
Active Control
Placebo Group
Group I: Ischemic Conditioning HighActive Control1 Intervention
Blood flow restriction with high compression
Group II: Ischemic Conditioning LowPlacebo Group1 Intervention
Blood flow restriction with low compression

Find a Location

Who is running the clinical trial?

University of Illinois at ChicagoLead Sponsor
639 Previous Clinical Trials
1,568,923 Total Patients Enrolled
1 Trials studying Peripheral Arterial Disease
146 Patients Enrolled for Peripheral Arterial Disease
American Heart AssociationOTHER
346 Previous Clinical Trials
4,971,408 Total Patients Enrolled
10 Trials studying Peripheral Arterial Disease
778 Patients Enrolled for Peripheral Arterial Disease
Lindsay Slater, PhDPrincipal InvestigatorUniversity of Illinois at Chicago

Media Library

Ischemic Conditioning High - Active Comparator Clinical Trial Eligibility Overview. Trial Name: NCT04937179 — N/A
Ischemic Conditioning High - Active Comparator 2023 Treatment Timeline for Medical Study. Trial Name: NCT04937179 — N/A
Peripheral Arterial Disease Research Study Groups: Ischemic Conditioning Low, Ischemic Conditioning High
Peripheral Arterial Disease Clinical Trial 2023: Ischemic Conditioning High - Active Comparator Highlights & Side Effects. Trial Name: NCT04937179 — N/A
~24 spots leftby Nov 2025
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Back to top